HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, ...
Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...
The funding supports Chiral’s mission to make post-silicon computing chips based on nanomaterials manufacturable at wafer scale and to unlock the next generation of chips beyond the limits of ...
This article is for informational purposes only. It is not medical advice. Weight management concerns should be evaluated by a qualified healthcare professional. Hims GLP-1 Weight Loss is a ...
Event: Biotricity Fiscal 2026 Third Quarter Financial Results and Business Update Call Date: Wednesday, February 11, 2026 Time: 4:30 PM ET (1:30 PM PT) Toll Free: 1-877-269-7751 International: ...
Starting 2/2/16, the new Nashville location will offer partial hospitalization (PHP), intensive outpatient (IOP), and outpatient programs (OP), as well as sober living facilities, in Renaissance ...
CHARLOTTE, NC, Feb. 05, 2026 (GLOBE NEWSWIRE) -- His Choice Health today announced the upcoming opening of its newest clinic in Charlotte, targeted late February 2026, bringing its highly regarded, ...
Additionally, a webcast replay of the conference call will be available on the Investors section of the Company’s website following the call. Dentsply Sirona is the world’s largest diversified ...
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside ...
The FDA distinguishes between FDA-approved medications and compounded formulations. FDA-approved medications like Wegovy, Ozempic, Mounjaro, and Zepbound have undergone rigorous clinical trials for ...
Adjusted EBITDA (non-GAAP) was $4.1 million for the fourth quarter of 2025, compared to a loss of $16.4 million for the fourth quarter of the prior year. Excluding revenue generated from the Genentech ...
Ascentage Pharma will be conducting a multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results